NCT01408563 · OUTCOME

Rate of Post-transplant Lymphoma

Reduced Intensity Double Umbilical Cord Blood Transplantation · Source last updated 2019-01-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 2.5 years

What was measured

The number of participants that were found to have lymphoma post-transplant.

Groups in this outcome

Fludarabine/Melphalan/TBI

All patients receive same therapy Fludarabine: 30 mg/m2/day IV x 6 days Melphalan: 100 mg/m2/day IV x 1 day Total Body Radiation: 200 cGy on Day 0 Cord Blood: 2 cord blood units IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Fludarabine/Melphalan/TBI	31

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Fludarabine/Melphalan/TBI	0	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
0

denoms

counts
group Id
OG000
value
31
units
Participants

description

The number of participants that were found to have lymphoma post-transplant.

groups

description
All patients receive same therapy Fludarabine: 30 mg/m2/day IV x 6 days Melphalan: 100 mg/m2/day IV x 1 day Total Body Radiation: 200 cGy on Day 0 Cord Blood: 2 cord blood units IV
id
OG000
title
Fludarabine/Melphalan/TBI

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

2.5 years

title

Rate of Post-transplant Lymphoma

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice